Shi Li

机构：Shandong University, University of South Carolina, Dalian University of Technology, Dalian Municipal Central Hospital, Shandong Provincial Hospital, University of Chinese Academy of Sciences, Southern Medical University · ORCID：0009-0003-2901-0114

发表论文 16 篇 · 总被引 1168 次 · h-index 7

代表论文

• Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial (2019 · The Lancet · 被引 1022)
• Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial (2025 · Nature Medicine · 被引 42)
• Interim Effectiveness and Safety Comparison of Bedaquiline-Containing Regimens for Treatment of Diabetic Versus Non-Diabetic MDR/XDR-TB Patients in China: A Multicenter Retrospective Cohort Study (2021 · Infectious Diseases and Therapy · 被引 29)
• Chinese Position Paper on Biologic Therapy for Chronic Rhinosinusitis With Nasal Polyps (2025 · Allergy · 被引 24)
• Red blood cell distribution width as a predictor of survival in nasal-type, extranodal natural killer/T-cell lymphoma (2017 · Oncotarget · 被引 20)
• A Novel Nomogram for Predicting Postsurgical Intra-abdominal Infection in Gastric Cancer Patients: a Prospective Study (2018 · Journal of Gastrointestinal Surgery · 被引 15)